Going Global Weekly Report: Innovative Drugs Win Dense FDA Clearances; SHEIN and Mech-Mind Lead the Hong Kong Listing Wave - 20260828

Outbound M&A

1. GUSHENGTANG (02273.HK): Announced on 27 August that its subsidiary Gushengtang Malaysia Sdn. Bhd. entered into sale and purchase agreements with the shareholders of three Malaysian traditional Chinese medicine (TCM) institutions to acquire 100% of YC TCM (Taman Segar) Sdn. Bhd., YC TCM Sdn. Bhd. and SWS Medical Sdn. Bhd., all of which are primarily engaged in TCM consultation and treatment services. Upon completion, the targets will be consolidated into the group's consolidated financial statements. The consideration will be funded by the net proceeds from the placement and convertible bonds and idle funds, and the transactions do not constitute connected transactions.

Outbound Cooperation

1. WAI CHUN BIOTEC (00660.HK): Announced on 26 August the signing of strategic cooperation memoranda of understanding with multiple parties for the integrated AI digital infrastructure ecosystem project at the Pahang Aerotropolis in Malaysia, with a master planned area of over 1,200 acres and an initial-phase IT load of 300 MW.

2. YANCOAL AUS (03668.HK): Announced on 24 August an increase in the annual cap under its Glencore framework coal sales agreement for the year ending 31 December 2026 from USD 350 million to USD 750 million, mainly due to expanded spot coal purchase demand amid Middle East conflicts and higher HVO spot sales; first-half transaction value totaled approximately USD 215 million.

Overseas Projects and Operations

1. CHINA BAOLI TEC (00164.HK): Announced on 26 August that its Mongolian iron ore project has entered the construction phase: the project partner has completed procurement of core equipment and shipped it to the mine site, and the company has dispatched a technical expert team to assist with installation and commissioning, with the first batch of processed iron ore concentrate expected shortly; infrastructure for its Mongolian coal mine project has been completed and recruitment has commenced.

2. JIAXIN INTL RES (03858.HK): Announced on 25 August that its subsidiary ZV, through public tender, entered into a mining construction contract with CCECC's Kazakhstan branch for the expansion of No. 1 tailings storage facility under the Bakuta tungsten mine project, with an initial contract price of approximately RMB 257 million (tax inclusive) and a cap of approximately RMB 306 million.

Overseas Orders and Contract Wins

1. MOBI DEV (00947.HK): Announced on 27 August that, during the 2026 FIFA World Cup in the US, Canada and Mexico, it will supply high-performance multi-beam antenna products for three World Cup venues in Mexico in partnership with local operators, with an estimated initial collaboration of over USD 1 million and continued signal coverage support for densely populated areas of Mexico thereafter.

2. PATEO (02889.HK): Announced on 26 August that it has entered the global supply system of a leading international automotive group for the first time, winning program awards across the customer's global models of a premium luxury brand and the export models of a mid-to-high-end brand, covering core overseas markets including Europe, the Middle East and South America, supplying high-end intelligent cockpit domain controllers built on Qualcomm's fourth-generation Snapdragon 8295 platform along with AI in-vehicle interaction systems.

Outbound Financing

1. SHEIN-W (00625.HK): Launched its global offering on 24 August, initially offering 279,992,500 Class B shares, comprising 27,999,300 shares in the Hong Kong public offering and 251,993,200 shares in the international offering, at a maximum offer price of HKD 49.50 per share, with Goldman Sachs, Morgan Stanley and JPMorgan as joint sponsors.

2. LEADERDRIVE (688017.SH): On 26 August, its board of directors approved a resolution to issue H-shares and list on the Main Board of The Stock Exchange of Hong Kong Limited, aimed at deepening its global strategic layout; the proposal remains subject to shareholder approval and filing/approval by the CSRC, the Stock Exchange and other regulators.

3. LONGSYS: Passed the HKEX listing hearing, with CITIC Securities Co., Ltd. and Citi as joint sponsors; the company was the world's second-largest independent semiconductor memory manufacturer by 2025 storage product revenue.

4. Mech-Mind Robotics (09615.HK): Launched its global offering on 24 August, initially offering 23,140,590 H-shares, comprising 1,157,040 shares in the Hong Kong public offering and 21,983,550 shares in the international offering, at a maximum offer price of HKD 101.70 per share.

5. Nazhen Technology: Received CSRC filing for overseas listing, planning to issue up to 310,855,000 overseas-listed ordinary shares on The Stock Exchange of Hong Kong Limited.

Regulatory and Compliance

1. CSPC PHARMA (01093.HK): Announced on 26 August that its PD-1/IL-15 bispecific fusion protein SYS6090 has been granted Fast Track designation by the US FDA for the treatment of MSS or pMMR metastatic colorectal cancer that has progressed after prior standard therapy.

2. CSPC PHARMA (01093.HK): Announced on 25 August that its recombinant respiratory syncytial virus (RSV) vaccine SYS6057 has been cleared by the US FDA to initiate clinical trials for the prevention of RSV-associated lower respiratory tract disease in people aged 60 and above.

3. BAO PHARMA-B (02659.HK): Announced on 24 August that KJ015, a subcutaneous formulation of a HER2-targeting bispecific antibody, has been cleared by the US FDA to initiate clinical trials.

4. ANTENGENE-B (06996.HK): Announced on 25 August that the Phase I ATTRACT study of its CD19/CD3 bispecific T-cell engager antibody ATG-201 has been approved by an Australian Human Research Ethics Committee.

NewTimeSpace Going-Global Observations

Main-line assessment: This week, two clear threads run through Chinese companies' global expansion—dense regulatory clearances for innovative drugs overseas, and a renewed heating-up of the Hong Kong listing and financing channel.

1. Pharmaceutical going-global enters a regulatory payoff period: Multiple self-developed drugs from CSPC PHARMA, BAO PHARMA and ANTENGENE have successively received clinical or qualification recognition from the US FDA and Australian regulators, with targets spanning bispecific antibodies, fusion proteins, vaccines and cell engagers; pipeline structures continue to diversify, and the going-global echelon is shifting from single-product breakthroughs to clustered pipeline advancement.

2. The structure of Hong Kong financing vehicles is broadening: SHEIN and Mech-Mind have launched global offerings, LONGSYS has passed its listing hearing, and LEADERDRIVE and Nazhen Technology are advancing H-share processes; going-global players are extending from traditional manufacturing and resources to technology and consumer platforms such as fashion e-commerce, robotics and semiconductor memory, visibly widening the industry coverage of the capital channel.

3. Resources and orders are advancing overseas in tandem: Mongolia's iron ore project has entered the construction phase and the Kazakhstan tungsten tailings facility contract has been signed, moving resource projects from exploration and planning into construction and output; the World Cup venue antenna supply in Mexico and global program awards from a leading automaker show that the overseas penetration of communications and intelligent cockpit supply chains is strengthening in tandem.

Trend wrap-up: Overall, the focus of going-global is shifting from single-product and engineering exports to multidimensional coordination of technology, capital and channels, with the industry structure showing a differentiated pattern of technology and pharmaceuticals leading while resources and manufacturing underpin.

This article is for information compilation only and does not constitute investment advice.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.